Bone Health Technologies (BHT), a company specialized in the development of non-pharmacological solutions to improve bone health and reduce fractures, has announced the acquisition of Wellen, a Brooklyn-based health technology company specializing in exercise-based osteoporosis care. This strategic move aims to create a comprehensive, multi-modal bone health solution.
The acquisition of Wellen marks a significant step toward BHT’s vision of providing a holistic bone health platform. The platform will be anchored by BHT’s FDA-cleared Osteoboost vibration therapy belt, set to launch in late 2024. Wellen CEO Priya Patel will join BHT as Chief Product Officer to spearhead the development of layered services aimed at optimizing outcomes for individuals with low bone density.
“We’re thrilled to welcome Wellen to the BHT team,” said Laura Yecies, CEO of Bone Health Technologies. “One-in-two women and one-in-four men will suffer an osteoporotic fracture in their lifetime. Priya and the Wellen team have built the gold standard for personalized exercise-based care designed by physical therapists to strengthen bones and reduce the risk of falls and fractures. The Wellen program will bring tremendous value to our platform.”
The Wellen exercise program, known for its personalized and science-backed approach, will remain active and supported for both existing and new members. This integration aligns with BHT’s holistic approach to bone health, which combines customized exercise, nutrition, tracking, and more.
“Anticipation is high for the launch of Osteoboost among both patients and healthcare professionals, and our science-backed osteoporosis exercise platform is a natural fit,” said Priya Patel, CEO of Wellen. “New treatments for low bone mass have been few and far between for a long time and too often have focused on a single type of treatment. I couldn’t be happier to join BHT and continue making a difference for people with low bone density.”
Patel further explained, “Osteoboost is the therapeutic anchor to BHT’s holistic, non-pharmacological approach to bone health. By layering customized exercise, nutrition, tracking, and more, we will be able to offer patients not only convenience but better results and a stronger, more active life.”
Currently, an estimated 64 million Americans—and hundreds of millions more worldwide—are at risk of life-altering spinal and hip fractures due to osteopenia and osteoporosis. While pharmacological interventions exist, patient acceptance is low due to side effects. The launch of Osteoboost, expected by the end of 2024, aims to address this issue with a precision-targeted vibration therapy belt as part of a 360° bone health solution.
The acquisition of Wellen follows several significant milestones for BHT, including FDA clearance of Osteoboost as a Class II De Novo Breakthrough medical device, and the award of the company’s fifth patent.
